The recombinant human (EGF) market is estimated to be valued at US$ 12246.47 Mn in 2023 and is expected to exhibit a CAGR of 9.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Recombinant human (EGF) is a growth factor protein that stimulates cellular growth, proliferation, and differentiation by binding to its receptor EGFR. It is commonly used in cell culture media to support the growth of epithelial cells and fibroblasts. Some key application areas include biopharmaceutical manufacturing, tissue engineering & regeneration, wound healing, and oncology research.
Market Dynamics:
Two major factors driving the growth of this market are:
Growing biopharmaceutical industry: Production of therapeutic proteins and monoclonal antibodies for various diseases requires large amounts of cells and fermentation media added with supplements like recombinant human EGF. This is propelling the demand from biopharmaceutical manufacturers.
Advances in regenerative medicine: EGF plays a crucial role in tissue healing and regeneration processes. Researchers are exploring its potential for regenerative therapies involving wound healing, skin grafts, and tissue-engineered skin substitutes. This is fueling the development and commercialization of novel regenerative products containing recombinant EGF.
The shift towards single-use bioprocessing technologies along with emergence of advanced cell culture methods like 3D bioprinting and organoids are expected to open new avenues for recombinant human EGF during the forecast period. However, high costs associated with manufacturing recombinant proteins may hamper market growth to some extent.
SWOT Analysis
Strength:
- Recombinant human EGF has significant therapeutic applications in wound healing.
- Availability of clear regulatory guidelines for approval and marketing of recombinant human EGF.
- Growing biopharmaceutical industry and R&D investments in cell and gene therapies.
Weakness:
- High production costs involved due to complex fermentation and purification processes.
- Requirement of specialized infrastructure and expertise for manufacturing recombinant proteins.
Opportunity:
- Increasing prevalence of chronic wounds such as diabetic foot ulcers and pressure ulcers globally.
- Expanding application scope in regenerative medicine and tissue engineering fields.
Threats:
- Commercial availability of alternative wound healing drugs and therapies.
- Stringent regulatory norms for biosimilars market approval.
Key Takeaways
The Global Recombinant Human EGF Market Size is expected to witness high growth, exhibiting CAGR of 9.3% over the forecast period, due to increasing prevalence of chronic wounds worldwide.
Regional analysis
North America dominated the global market in 2023 and is expected to maintain its lead over the forecast period. This is attributed to rising incidence of chronic wounds and strong presence of key market players in the region. Asia Pacific is anticipated to be the fastest growing market owing to improving healthcare infrastructure and rising medical tourism in countries like China, India and Japan.
Key players
Key players operating in the recombinant human EGF market are Thermo Fisher Scientific, FUJIFILM Irvine Scientific, Inc., ScienCell Research Laboratories, R&D Systems, Abcam PLC, Cell Sciences, Inc., Eurofins DiscoverX, PeproTech, Inc., RayBiotech, Inc., Prospec-Tany TechnoGene Ltd., Miltenyi Biotec, Tonbo Biosciences, BioLegend, Inc., EnQuire BioReagents, STEMCELL Technologies Inc., Cell Guidance Systems Ltd., Creative BioMart, Sino Biological Inc., and BioVision, Inc.
Read Our More Blogs : https://www.pressreleasebulletin.com/recombinant-human-egf-market-analysis-growth-forecast-outlook-2023-2030/
Sign in to leave a comment.